ILMN
Illumina, Inc. NASDAQ Listed Jul 28, 2000$138.67
Mkt Cap $21.0B
52w Low $75.24
79.0% of range
52w High $155.53
50d MA $127.05
200d MA $118.71
P/E (TTM)
24.8x
EV/EBITDA
14.9x
P/B
7.6x
Debt/Equity
0.9x
ROE
31.2%
P/FCF
22.1x
RSI (14)
—
ATR (14)
—
Beta
1.49
50d MA
$127.05
200d MA
$118.71
Avg Volume
1.8M
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
5200 Illumina Way · San Diego, CA 92122 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 1.05 | 1.15 | +9.5% | 126.74 | +5.1% | +7.1% | +10.0% | +9.7% | +12.5% | +9.4% | — |
| Feb 5, 2026 | AMC | 1.24 | 1.35 | +8.9% | 133.61 | -5.7% | -10.4% | -12.2% | -10.7% | -12.9% | -14.3% | — |
| Oct 30, 2025 | AMC | 1.17 | 1.34 | +14.5% | 99.01 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% | — |
| Jul 31, 2025 | AMC | 1.02 | 1.19 | +16.7% | 102.71 | -9.8% | -7.8% | -4.2% | -4.8% | -8.1% | -7.0% | — |
| May 8, 2025 | AMC | 0.94 | 0.97 | +3.2% | 79.58 | -0.1% | -4.8% | +2.5% | +0.9% | -1.7% | +1.7% | — |
| Feb 6, 2025 | AMC | 0.92 | 0.86 | -6.5% | 122.80 | -9.4% | -9.6% | -14.5% | -18.0% | -15.7% | -17.1% | — |
| Nov 4, 2024 | AMC | 0.88 | 1.14 | +29.7% | 153.49 | -3.5% | +1.0% | -1.1% | +1.1% | -1.6% | -1.3% | — |
| Aug 6, 2024 | AMC | 0.11 | 0.36 | +228.5% | 116.36 | +3.0% | +4.1% | +8.9% | +6.2% | +7.0% | +2.9% | — |
| May 2, 2024 | AMC | 0.04 | 0.09 | +106.4% | 120.50 | +2.5% | -4.9% | -4.0% | -9.0% | -10.8% | -10.2% | — |
| Feb 8, 2024 | AMC | 0.02 | 0.14 | +686.1% | 139.29 | +0.3% | -3.8% | -2.3% | -6.7% | -1.8% | +1.9% | — |
| Nov 9, 2023 | AMC | 0.13 | 0.33 | +153.8% | 103.97 | -12.1% | -8.1% | -13.3% | -8.9% | -6.4% | -11.0% | — |
| Aug 9, 2023 | AMC | 0.02 | 0.32 | +1636.5% | 179.29 | -3.0% | +0.3% | -2.2% | -5.1% | -4.6% | -8.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Barclays | Maintains | Underweight → Underweight | — | $126.74 | $133.22 | +5.1% | +7.1% | +10.0% | +9.7% | +12.5% | +9.4% |
| May 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $126.74 | $133.22 | +5.1% | +7.1% | +10.0% | +9.7% | +12.5% | +9.4% |
| May 1 | JP Morgan | Maintains | Neutral → Neutral | — | $126.74 | $133.22 | +5.1% | +7.1% | +10.0% | +9.7% | +12.5% | +9.4% |
| May 1 | Canaccord Genuity | Maintains | Hold → Hold | — | $126.74 | $133.22 | +5.1% | +7.1% | +10.0% | +9.7% | +12.5% | +9.4% |
| Feb 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $119.72 | $119.72 | +0.0% | -2.1% | -0.3% | -2.8% | -4.4% | -2.4% |
| Feb 6 | JP Morgan | Maintains | Neutral → Neutral | — | $133.61 | $125.99 | -5.7% | -10.4% | -12.2% | -10.7% | -12.9% | -14.3% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $150.28 | $149.36 | -0.6% | +1.8% | +1.2% | -0.3% | -0.4% | -3.6% |
| Jan 26 | Canaccord Genuity | Maintains | Hold → Hold | — | $150.28 | $149.36 | -0.6% | +1.8% | +1.2% | -0.3% | -0.4% | -3.6% |
| Jan 20 | Stifel | Maintains | Buy → Buy | — | $141.65 | $137.78 | -2.7% | +3.9% | +7.6% | +8.7% | +6.1% | +8.0% |
| Jan 7 | TD Cowen | Maintains | Hold → Hold | — | $147.11 | $146.95 | -0.1% | +2.1% | -0.9% | -4.1% | -1.1% | -0.1% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $134.35 | $134.36 | +0.0% | +5.2% | +9.5% | +11.8% | +8.5% | +5.0% |
| Dec 22 | Canaccord Genuity | Maintains | Hold → Hold | — | $134.78 | $135.60 | +0.6% | +2.1% | +1.0% | +0.4% | +0.1% | -0.2% |
| Dec 15 | JP Morgan | Maintains | Neutral → Neutral | — | $134.87 | $134.90 | +0.0% | +0.0% | -2.5% | -3.9% | -3.2% | -0.1% |
| Dec 15 | Barclays | Maintains | Underweight → Underweight | — | $134.87 | $134.90 | +0.0% | +0.0% | -2.5% | -3.9% | -3.2% | -0.1% |
| Oct 31 | Barclays | Maintains | Underweight → Underweight | — | $99.01 | $106.91 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% |
| Oct 31 | Evercore ISI | Maintains | Outperform → Outperform | — | $99.01 | $106.91 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% |
| Oct 31 | Baird | Maintains | Neutral → Neutral | — | $99.01 | $106.91 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% |
| Oct 31 | JP Morgan | Maintains | Neutral → Neutral | — | $99.01 | $106.91 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% |
| Oct 31 | UBS | Maintains | Neutral → Neutral | — | $99.01 | $106.91 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% |
| Oct 31 | Canaccord Genuity | Maintains | Hold → Hold | — | $99.01 | $106.91 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% |
| Oct 31 | TD Cowen | Maintains | Hold → Hold | — | $99.01 | $106.91 | +8.0% | +24.8% | +21.2% | +18.0% | +23.7% | +22.3% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $101.02 | $101.36 | +0.3% | -4.3% | -3.2% | -4.5% | -7.1% | -5.9% |
| Oct 2 | Barclays | Maintains | Underweight → Underweight | — | $102.26 | $103.00 | +0.7% | -2.9% | -0.1% | -1.2% | -5.5% | -4.4% |
| Aug 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $94.66 | $95.03 | +0.4% | +4.0% | +3.3% | -0.2% | +0.9% | -0.1% |
| Aug 1 | Barclays | Maintains | Underweight → Underweight | — | $102.71 | $92.61 | -9.8% | -7.8% | -4.2% | -4.8% | -8.1% | -7.0% |
| Aug 1 | UBS | Maintains | Neutral → Neutral | — | $102.71 | $92.61 | -9.8% | -7.8% | -4.2% | -4.8% | -8.1% | -7.0% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $102.71 | $92.61 | -9.8% | -7.8% | -4.2% | -4.8% | -8.1% | -7.0% |
| Aug 1 | Canaccord Genuity | Maintains | Hold → Hold | — | $102.71 | $92.61 | -9.8% | -7.8% | -4.2% | -4.8% | -8.1% | -7.0% |
| Aug 1 | JP Morgan | Maintains | Neutral → Neutral | — | $102.71 | $92.61 | -9.8% | -7.8% | -4.2% | -4.8% | -8.1% | -7.0% |
| Jul 28 | Baird | Maintains | Neutral → Neutral | — | $109.30 | $109.40 | +0.1% | +0.5% | -0.5% | -2.4% | -6.0% | -13.4% |
| Jul 11 | Scotiabank | Downgrade | Sector Outperform → Sector Perform | — | $100.05 | $98.50 | -1.5% | -0.8% | -1.5% | -2.9% | -3.1% | -2.1% |
| Jul 9 | Citigroup | Downgrade | Neutral → Sell | — | $99.27 | $96.25 | -3.0% | -1.8% | +0.8% | -0.0% | -0.7% | -2.1% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $97.15 | $97.42 | +0.3% | +2.2% | +0.3% | +3.0% | +2.2% | +1.4% |
| Jun 24 | Barclays | Maintains | Underweight → Underweight | — | $90.61 | $91.54 | +1.0% | +1.0% | +2.9% | +3.9% | +4.6% | +5.3% |
| Jun 11 | Canaccord Genuity | Maintains | Hold → Hold | — | $87.98 | $88.91 | +1.1% | -0.5% | +0.2% | -1.2% | +2.6% | +1.7% |
| May 20 | Stephens & Co. | Maintains | Overweight → Overweight | — | $82.95 | $82.91 | -0.0% | +1.5% | -4.3% | -2.9% | -3.1% | -0.6% |
| May 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $78.21 | $80.02 | +2.3% | +3.4% | +6.9% | +6.1% | +7.7% | +1.5% |
| May 12 | Canaccord Genuity | Maintains | Hold → Hold | — | $75.76 | $79.28 | +4.6% | +7.7% | +6.0% | +3.2% | +6.8% | +10.4% |
| May 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $75.76 | $79.28 | +4.6% | +7.7% | +6.0% | +3.2% | +6.8% | +10.4% |
| May 9 | Guggenheim | Maintains | Buy → Buy | — | $79.58 | $79.50 | -0.1% | -4.8% | +2.5% | +0.9% | -1.7% | +1.7% |
| May 9 | JP Morgan | Maintains | Neutral → Neutral | — | $79.58 | $79.50 | -0.1% | -4.8% | +2.5% | +0.9% | -1.7% | +1.7% |
| Apr 29 | Canaccord Genuity | Maintains | Hold → Hold | — | $77.22 | $76.61 | -0.8% | -0.2% | +0.5% | -0.9% | +0.9% | +1.2% |
| Apr 10 | Barclays | Maintains | Underweight → Underweight | — | $76.30 | $74.50 | -2.4% | -6.6% | -2.0% | -1.6% | -2.2% | -3.6% |
| Apr 8 | RBC Capital | Maintains | Outperform → Outperform | — | $73.45 | $75.76 | +3.1% | -4.3% | +3.9% | -3.0% | +1.8% | +2.2% |
| Apr 7 | Citigroup | Maintains | Neutral → Neutral | — | $74.16 | $70.61 | -4.8% | -1.0% | -5.2% | +2.9% | -3.9% | +0.8% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $84.52 | $84.63 | +0.1% | -0.4% | -0.6% | +1.3% | +1.4% | +0.8% |
| Mar 11 | Canaccord Genuity | Maintains | Hold → Hold | — | $85.97 | $88.50 | +2.9% | -1.7% | -2.1% | -2.2% | -0.4% | -0.3% |
| Mar 11 | Stephens & Co. | Maintains | Overweight → Overweight | — | $85.97 | $88.50 | +2.9% | -1.7% | -2.1% | -2.2% | -0.4% | -0.3% |
| Mar 5 | Baird | Maintains | Neutral → Neutral | — | $84.89 | $85.00 | +0.1% | +0.9% | -0.3% | +2.0% | +1.3% | -0.4% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $84.20 | $80.74 | -4.1% | +0.8% | +1.8% | +0.5% | +2.9% | +2.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | Wedel Christensen JakobOff | SVP, Strategy/Corp Development | Sell | 700 | $139.04 | $97K | 15,056 | +2.29% | — |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I cannot provide a meaningful analysis as the filing excerpt lacks essential details about the executive change at Illumina, including who departed, their role, and replacement plans—information critical for assessing leadership stability and strategic direction impacts.
Apr 2
8-K
Illumina Inc -- 8-K Filing
Illumina reported its Q4 and full-year 2025 financial results, providing investors with updates on the company's revenue, profitability, and operational performance for the completed fiscal period.
Feb 5
Data updated apr 25, 2026 3:14pm
· Source: massive.com